MedTrace Logo

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

NCT05328102 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.

Conditions

  • Diffuse Large-cell B-cell Lymphoma

Interventions

BIOLOGICAL

Plamotamab

Biological

BIOLOGICAL

Tafasitamab

Biological

DRUG

Lenalidomide

Drug

Sponsors & Collaborators

  • Xencor, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Chiarella · Senior Director, Clinical Science, Clinical Development

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2023-02-21
Completion
2023-02-21
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05328102 on ClinicalTrials.gov